Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features

Cancer Science

Volumn 104, Issue 2, 2013, Pages 266-273

  Matsubara, Daisuke ^a,b   Kishaba, Yuka ^a   Ishikawa, Shumpei ^c   Sakatani, Takashi ^a   Oguni, Sachiko ^a   Tamura, Tomoko ^a   Hoshino, Hiroko ^a   Sugiyama, Yukihiko ^a   Endo, Shunsuke ^a   Murakami, Yoshinori ^b   Aburatani, Hiroyuki ^d   Fukayama, Masashi ^c   Niki, Toshiro ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRG1 PROTEIN; BRM PROTEIN; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; THYROID TRANSCRIPTION FACTOR 1; UVOMORULIN; VIMENTIN;

ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GENETIC CORRELATION; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL;

ADENOCARCINOMA; CADHERINS; CELL LINE, TUMOR; DNA HELICASES; DNA-BINDING PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; KERATIN-7; LUNG NEOPLASMS; MUTATION; NUCLEAR PROTEINS; PHENOTYPE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS;

EID: 84873720537     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12065     Document Type: Article

References (19)

1. Statistics and Information Department. Vital Statistics, 2000. Tokyo: Ministry of Health, Labor and Welfare, 2001.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
3. Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol 2011; 6: 1601-12.
4. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11: 481-92.
5. Jones S, Wang TL, Shih IM et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-31.
6. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539-42.
7. Gui Y, Guo G, Huang Y et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011; 43: 875-8.
8. Zang ZJ, Cutcutache I, Poon SL et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 2012; 44: 570-4.
9. Medina PP, Romero OA, Kohno T et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 2008; 29: 617-22.
10. Glaros S, Cirrincione GM, Palanca A, Metzger D, Reisman D. Targeted knockout of BRG1 potentiates lung cancer development. Cancer Res 2008; 68: 3689-96.
11. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003; 63: 560-6.
12. Fukuoka J, Fujii T, Shih JH et al. Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res 2004; 10: 4314-24.
13. Matsubara D, Ishikawa S, Sachiko O et al. Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas. Am J Pathol 2010; 177: 2191-204.
14. Takeuchi T, Tomida S, Yatabe Y et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006; 24: 1679-88.
15. Shedden K, Taylor JM, Enkemann SA et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008; 14: 822-7.
16. Wiegand KC, Lee AF, Al-Agha OM et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011; 224: 328-33.
17. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-43.
18. Maeda D, Mao TL, Fukayama M et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 2010; 11: 5120-8.
19. Richly H, Lange M, Simboeck E, Di Croce L. Setting and resetting of epigenetic marks in malignant transformation and development. BioEssays 2010; 32: 669-79.